Anne-Marie Koop

318 36. Fang Y-H, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer SL. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: Exploiting Randle’s cycle. J Mol Med S.L. Archer, Medicine/Cardiology, University of Chicago, Chicago, IL 60637, United States; 2012;90:31–43. 37. Rumsey WL, Abbott B, Bertelsen D, Mallamaci M, Hagan K, Nelson D, Erecinska M. Adaptation to hypoxia alters energy metabolism in rat heart. Am J Physiol - Hear Circ Physiol W.L. Rumsey, Zeneca Pharmaceuticals, Wilmington, DE 19850-5437, United States; 1999;276:H71–H80. 38. ZhangW-H, Qiu M-H, Wang X-J, Sun K, Zheng Y, Jing Z-C. Up-regulation of hexokinase1 in the right ventricle of monocrotaline induced pulmonary hypertension. Respir Res Y. Zheng, First Hospital of Jilin University, Center of Cardiovascular Disease, Changchun, China; 2014;15. 39. Piao L, Sidhu VK, Fang YH, Ryan JJ, Parikh KS, Hong Z, Toth PT, Morrow E, Kutty S, Lopaschuk GD, Archer SL. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med 2012;29:1–14. 40. Sun X-Q, Zhang R, Zhang H-D, Yuan P, Wang X-J, Zhao Q-H, Wang L, Jiang R, Jan Bogaard H, Jing Z-C. Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis. Hypertens Res Z.-C. Jing, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Peking Union Medical College, Chinese Academy Medical Science, Beijing, China; 2016;39:302–311. 41. Ryan JJ, Huston J, Kutty S, Hatton ND, Bowman L, Tian L, Herr JE, Johri AM, Archer SL. Right Ventricular Adaptation and Failure in Pulmonary Arterial Hypertension. Can J Cardiol Canadian Cardiovascular Society; 2015;31:391–406. 42. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006;367:1315; author reply 1315-6. 43. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215– 228. 44. Bourajjaj M, Armand AS, Costa Martins PA Da, Weijts B, Nagel R Van Der, Heeneman S, Wehrens XH, Windt LJ De. NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem 2008;283:22295–22303. 45. Windt LJ De, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TR, Monte F del, Hajjar RJ, Molkentin JD. Targeted inhibition of calcineurin in pressure- overload cardiac hypertrophy in vivo. Proc Natl Acad Sc i 2001;98:3322–3327. 46. Wilkins BJ, Windt LJ De, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD. Targeted Disruption of NFATc3, but Not NFATc4, Reveals an Intrinsic Defect in Calcineurin- Mediated Cardiac Hypertrophic Growth. Mol Cell Biol 2002;22:7603–7613. 47. Bartelds B, Borgdorff M a., Smit-Van Oosten A, Takens J, Boersma B, Nederhoff MG, Elzenga NJ, Gilst WH Van, Windt LJ De, Berger RMF. Differential responses of the right ventricle to abnormal loading conditions in mice: Pressure vs. volume load. Eur J Heart Fail 2011;13:1275–1282.